Shares in Halozyme Therapeutics jump 20% on Phase II results

5 January 2017
2019_biotech_test_vial_discovery_big

American biotech firm Halozyme Therapeutics (Nasdaq: HALO) has released positive news from a much-anticipated Phase II trial of the company’s lead investigational compound.

PEGPH20, an anticancer agent, is designed to make existing treatments more effective by breaking down potential barriers to the tumor.

Shares in the company jumped more than 20% to $13 before markets opened. Strong investor interest continues to support higher than average volumes of trading in the company.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology